Ignacio I. Wistuba, MD

home / authors / ignacio-i-wistuba-md

Articles

Exciting NSCLC Data Updates from ESMO 2022

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

November 9th 2022

The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.

NSCLC Molecular Testing Recommendations for Community Hospitals

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

November 2nd 2022

Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.

Adjuvant Therapy in EGFR-Mutated NSCLC

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

November 2nd 2022

Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.

Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 26th 2022

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

The Role of Adjuvant Therapy in Patients with NSCLC

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 26th 2022

Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.

Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 19th 2022

Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.

The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 19th 2022

Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.

Updates in the Treatment of Stage I-IIIA NSCLC

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 17th 2022

The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.

Is There a Role for Liquid Biopsies in Early NSCLC?

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 17th 2022

Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.

Molecular Testing in Early NSCLC to Guide Treatment Decision Making

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 5th 2022

Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.

Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)

Heather Wakelee, MD;Bill W. Loo, MD;Ignacio I. Wistuba, MD;Jonathan Spicer, MD, PhD;Joshua Sabari, MD

October 5th 2022

A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.

Dr. Wistuba on Biomarkers for Immunotherapy in Lung Cancer

Ignacio I. Wistuba, MD

August 8th 2018

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Medicine, The University of Texas MD Anderson Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Dr. Wistuba on Maximizing Outcomes With Limited Tissue in Lung Cancer

Ignacio I. Wistuba, MD

October 11th 2016

Ignacio I. Wistuba, MD, chair, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, Anderson Clinical Faculty Chair for Cancer Treatment and Research, The University of Texas MD Anderson Cancer Center, discusses how pathologists maximize outcomes with limited tissue in patients with lung cancer.